Bristol Myers Squibb Surges to 129th Most Traded Stock with 44% Volume Spike

On April 9, 2025, Bristol Myers Squibb (BMY) experienced a significant surge in trading volume, with a turnover of 12.69 billion, marking a 44.34% increase from the previous day. This substantial rise in trading activity positioned BMY as the 129th most traded stock on the day.

Bristol Myers Squibb recently received FDA approval for the combination therapy of Opdivo and Yervoy, significantly enhancing its immunotherapy portfolio. This approval is based on the Phase 3 CheckMate-8HW trial, which demonstrated a 79% reduction in the risk of disease progression or death compared to chemotherapy in the first-line setting. The trial also showed a 38% reduction in the risk of disease progression or death compared to Opdivo monotherapy across all lines of therapy. This approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date, highlighting the efficacy and urgency of the treatment.

The approval of Opdivo plus Yervoy for previously untreated microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer (CRC) is a significant milestone. This dual immunotherapy approach has shown meaningful outcomes, potentially redefining traditional care for patients with this aggressive form of cancer. The trial demonstrated that the combination therapy met the dual primary endpoints of progression-free survival (PFS) when compared to Opdivo monotherapy across all lines of therapy and when compared to chemotherapy in the first-line setting. The safety profile of the combination remained consistent with previously reported data, with manageable adverse reactions.

Bristol Myers Squibb is committed to leveraging CAR T therapies against new targets, including autoimmune disorders. The company's success in cancer treatment has paved the way for exploring innovative therapies in other areas, aiming to address unmet medical needs and improve patient outcomes. The approval of Opdivo plus Yervoy underscores Bristol Myers Squibb's dedication to transforming patient lives through science and innovative medicines.